Endoscopic bariatric and metabolic therapies (EBMTs) have been developed for patients with obesity who are not candidates for, or do not desire, bariatric surgery. While gastric EBMTs are designed to treat obesity, small-bowel EBMTs are directed at treating metabolic diseases, with variable efficacy in weight loss. Additionally, some data also suggests that combination therapy using these endoscopic interventions and pharmacotherapy may act synergistically. This session will review the neurohormonal control of digestion, and then focus on the mechanisms of action of each of these minimally invasive interventions. Data from both human and animal-models will be presented in this symposium for the broad interest to clinicians and researchers.

Dr. Popov would like the audience to be aware that she may discuss the off-label use of bariatric endoscopic devices not yet approved in the US during this presentation. Dr. Schulman would like the audience to be aware that she may discuss the off-label use of devices used in endoscopic bariatric and metabolic therapy during this presentation. Dr. Thompson would like the audience to be aware that the majority of small bowel devices are investigational.

This session was jointly produced by The Obesity Society (TOS), American Society for Gastrointestinal Endoscopy (ASGE), and Association for Bariatric Endoscopy (ABE).